Goldenwell Biotech, INC. (GWLL) — SEC Filings

Q: What are the key financial highlights for Goldenwell Biotech, INC.?

Key financial highlights for Goldenwell Biotech, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Goldenwell Biotech, INC.?

Key executives at Goldenwell Biotech, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Goldenwell Biotech, INC. stock?

Risk factors for Goldenwell Biotech, INC. (GWLL) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Goldenwell Biotech, INC.?

Forward-looking statements and predictions from Goldenwell Biotech, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Goldenwell Biotech, INC.. Recent 10-Q filing on Dec 8, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Goldenwell Biotech, INC. on SEC EDGAR

Overview

Goldenwell Biotech, INC. (GWLL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 8, 2025: GOLDENWELL BIOTECH, INC. (GWLL) reported a net loss of $47,581 for the nine months ended September 30, 2025, a significant improvement from the $103,962 net loss in the same period of 2024. Revenue for the nine months ended September 30, 2025, was $62,500, entirely from service revenue, compared to

Sentiment Summary

Across 11 filings, the sentiment breakdown is: 2 bearish, 8 neutral, 1 mixed. The dominant filing sentiment for Goldenwell Biotech, INC. is neutral.

Filing Type Overview

Goldenwell Biotech, INC. (GWLL) has filed 6 10-Q, 3 8-K, 2 10-K with the SEC between Apr 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (11)

Goldenwell Biotech Narrows Losses, Boosts Service Revenue Amidst Going Concern — 10-Q · Dec 8, 2025 Risk: high
GOLDENWELL BIOTECH, INC. (GWLL) reported a net loss of $47,581 for the nine months ended September 30, 2025, a significant improvement from the $103,962 net los
Goldenwell Biotech Narrows Losses, Still Faces Going Concern Doubts — 10-Q · Sep 12, 2025 Risk: high
GOLDENWELL BIOTECH, INC. (GWLL) reported a net loss of $39,596 for the six months ended June 30, 2025, a significant improvement from the $80,897 net loss in th
Goldenwell Biotech Changes Certifying Accountant — 8-K · Aug 19, 2025 Risk: medium
Goldenwell Biotech, Inc. filed an 8-K on August 19, 2025, reporting a change in its certifying accountant as of July 24, 2025. The company's principal executive
Goldenwell Biotech Bets Big on Megalight Acquisition for Future Growth — 10-Q · May 27, 2025 Risk: high
GOLDENWELL BIOTECH, INC. (GWLL) reported no revenue for the quarter ended March 31, 2025, consistent with the prior year's quarter. The company's net income was
Goldenwell Biotech Files 2024 10-K — 10-K · May 15, 2025 Risk: low
Goldenwell Biotech, Inc. filed its 2024 10-K on May 15, 2025, reporting its fiscal year ending December 31, 2024. The company, incorporated in Nevada and headqu
Goldenwell Biotech Changes Certifying Accountant — 8-K · Jan 23, 2025 Risk: low
Goldenwell Biotech, Inc. filed an 8-K on January 23, 2025, to report a change in its certifying accountant. The company has appointed a new independent register
Goldenwell Biotech Files Q3 2024 10-Q — 10-Q · Nov 26, 2024 Risk: medium
Goldenwell Biotech, Inc. filed its Q3 2024 10-Q report on November 26, 2024, covering the period ending September 30, 2024. The company, incorporated in Nevada,
Goldenwell Biotech Files 8-K on Accountant Change — 8-K · Nov 15, 2024 Risk: medium
Goldenwell Biotech, Inc. filed an 8-K on November 15, 2024, reporting changes in its certifying accountant and filing financial statements and exhibits. The rep
Goldenwell Biotech Files Q2 2024 10-Q — 10-Q · Aug 22, 2024 Risk: low
Goldenwell Biotech, Inc. filed its 10-Q for the period ending June 30, 2024. The company, incorporated in Nevada and operating in the food and kindred products
Goldenwell Biotech Q1 2024: $300M Assets, $99M Liabilities — 10-Q · May 20, 2024 Risk: medium
Goldenwell Biotech, Inc. filed its Q1 2024 10-Q report on May 20, 2024, for the period ending March 31, 2024. The company's business address is 581 Boston Mills
Goldenwell Biotech, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 12, 2024 Risk: low
GOLDENWELL BIOTECH, INC. (GWLL) filed a Annual Report (10-K) with the SEC on April 12, 2024. Filed Form 10-K for the fiscal year ended December 31, 2023. Compan

Risk Profile

Risk Assessment: Of GWLL's 11 recent filings, 3 were flagged as high-risk, 4 as medium-risk, and 4 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Goldenwell Biotech, INC.'s most recent 10-Q filing (Dec 8, 2025):

Revenue: $62,500
Net Income: -$47,581
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $45,622
Operating Margin: N/A
Total Assets: $220,410
Total Debt: $315,233

Key Executives

Li, Yang
Shuang Liu

Industry Context

Goldenwell Biotech operates in the healthcare and supplements sector, a competitive industry characterized by research and development intensity and evolving consumer demands. The company is in its early development stage, focusing on R&D and production, suggesting it is aiming to carve out a niche in this dynamic market.

Top Tags

10-Q (4) · financials (4) · Biotech (3) · biotech (3) · Going Concern (2) · Net Loss (2) · Related Party Transactions (2) · Small Cap (2) · R&D (2) · auditor-change (2)

Key Numbers

Net Loss: $47,581 — for the nine months ended September 30, 2025, an improvement from $103,962 in 2024
Service Revenue: $62,500 — for the nine months ended September 30, 2025, up from $0 in 2024
Accumulated Net Loss: $1,407,226 — since inception, indicating significant historical losses
Cash Balance: $45,622 — as of September 30, 2025, down from $49,404 at December 31, 2024
Related Party Loan: $95,588 — outstanding from CEO Shuang Liu as of September 30, 2025
Common Shares Outstanding: 99,000,000 — as of September 30, 2025
General and Administrative Expenses: $103,781 — for the nine months ended September 30, 2025, an increase from $99,911 in 2024
Interest Expense: $6,300 — for the nine months ended September 30, 2025
Total Revenue: $37,797 — for the six months ended June 30, 2025, primarily from service revenue
Cash at End of Period: $76,507 — as of June 30, 2025, up from $49,404 at December 31, 2024
Outstanding Related-Party Loan: $95,588 — as of June 30, 2025, from CEO Shuang Liu
Total Liabilities: $338,133 — as of June 30, 2025, an increase from $271,433 at December 31, 2024
Shares of Common Stock: 99,000,000 — issued and outstanding as of June 30, 2025
Operating Expenses: $72,896 — for the six months ended June 30, 2025, down from $76,846 in 2024
Revenue: $0 — For the quarter ended March 31, 2025, indicating no operational revenue.

Related Companies

GDWL

Frequently Asked Questions

What are the latest SEC filings for Goldenwell Biotech, INC. (GWLL)?

Goldenwell Biotech, INC. has 11 recent SEC filings from Apr 2024 to Dec 2025, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of GWLL filings?

Across 11 filings, the sentiment breakdown is: 2 bearish, 8 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Goldenwell Biotech, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Goldenwell Biotech, INC. (GWLL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Goldenwell Biotech, INC.?

Key financial highlights from Goldenwell Biotech, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for GWLL?

The investment thesis for GWLL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Goldenwell Biotech, INC.?

Key executives identified across Goldenwell Biotech, INC.'s filings include Li, Yang, Shuang Liu.

What are the main risk factors for Goldenwell Biotech, INC. stock?

Of GWLL's 11 assessed filings, 3 were flagged high-risk, 4 medium-risk, and 4 low-risk.

What are recent predictions and forward guidance from Goldenwell Biotech, INC.?

Forward guidance and predictions for Goldenwell Biotech, INC. are extracted from SEC filings as they are enriched.